Lysogene is a French biopharmaceutical gene therapy company with lead programs in lysosomal storage disorders. Our advanced technology capitalizes on our differentiated knowledge of direct-to-brain administration of AAV vectors, allowing us to precisely target the root causes of the disease.

Role within Screen4Care

Lysogene will contribute to WP3.5 which aims to generate preliminary evidence on the cost-effectiveness of novel genetic NBS for diagnosing RDs and to provide a methodological framework for conducting cost-effectiveness studies in the context of genetic NBS for RDs.